Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zoono Group (ZNO) has spiked on the market today after revealing it earned NZ$11 million in sales over just 11 weeks this year
  • In a late-market announcement, Zoono revealed to shareholders the true extent of the increased demand caused by Covid-19
  • The pandemic has seen Zoono sell NZ$150,000 worth of sanitiser products every week since the start of March — in online sales alone
  • To meet the unprecedented demand, the company has had to relocate its Auckland operations to a “substantially” bigger facility
  • Shares in Zoono quickly soared after the announcement to close green by over 13 per cent, worth $1.54 each

For the past two months, Zoono Group (ZNO) has been in the spotlight as its sanitiser products are distributed across the globe to fight the spread of Covid-19.

While Zoono is one of few companies benefitting from the pandemic, the company revealed the true extent of this benefit in sales update to shareholders today.

In the late-market announcement, Zoono highlighted a whopping NZ$11 million (A$10.9) million in sales of its sanitiser products over the last 11 weeks — meaning the company is pulling in NZ$1 million in sales per week.

For reference, Zoono made NZ$1.715 million in sales for the entire first half of the 2020 financial year.

Online sales have been a major catalyst for the increased volume, with the company averaging NZ$150,000 per day of online sales alone since the start of March.

Importantly, the company’s recently-opened UK/EU sales office is officially profitable as sales boom. From this office, which was opened in 2018, Zoono has made NZ$1 million in sales this quarter and has over NZ$3 million in current orders.

Company management said Auckland operations have had to move to a “substantially” larger premises to cope with the dramatic increase in sales, with a team working all hours of every day to fulfil orders.

Firstly, any company specialising in hand and surface sanitation has seen a drastic increase in demand for its products as people do their best to protect themselves from the spread of the coronavirus.

Fellow ASX-listed Holista Colltech (HCT) is one such company who saw a spike in orders following the coronavirus outbreak.

Even companies not working in the healthcare space have branched out to create sanitiser just to meet the increased global demand. The Food Revolution Group (FOD), which typically operates in fruit and veggie products, received $2 million in orders just days after stepping into the world of sanitisation.

With Zoono already holding a strong position in the healthcare sector with its sanitiser products, it’s no surprise the company is among those cashing in from Covid-19.

Secondly, the tech behind Zoono’s products is drawing investor attention. Simply put, Zoono’s sanitiser bonds with any surface on which it is applied and attracts and then destroys bacteria and pathogens. The solution is non-toxic and lasts longer than conventional sanitiser and has been proven effective in stemming the spread of the coronavirus.

Shareholders seem pleased with today’s sales update, with Zoono shares seeing a sudden afternoon surge following the announcement. Shares in the company were marginally red for the majority of the day, but the 3:24 pm AEDT announcement saw them spike suddenly.

Shares closed 13.24 per cent higher at $1.54 each. This time last year, shares were worth just 12 cents.

ZNO by the numbers
More From The Market Herald
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) receives $524,000 R&D tax refund

Arovella Therapeutics (ALA) has received a refund from the Australian Taxation Office (ATO) of just over $524,000 for the financial year.

" FijiKava (ASX:FIJ) raises $2.67m via SPP

Australian-Fijian health and wellness company FijiKava (FIJ) has raised $2,679,000 via its share purchase plan (SPP).
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp Health (ASX:RAP) achieves regulatory approvals for cough counter application

ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering